Abstract
Severe fungal infections remain a significant cause of morbidity and mortality in neutropenic patients undergoing doseintensive chemotherapy for malignant diseases. Chronic disseminated candidiasis (CDC) is a life-threatening complication in neutropenic patients because of the lack of responsive hematopoietic precursor cells. Resolution of Candida organ lesions after hematopoietic reconstitution may take months. Here, we report the case of a 19-year-old neutropenic woman with relapsed acute myelogenous leukemia and candidiasis of liver, spleen, and kidneys. Antifungal treatment was initiated using fluconazole and caspofungin but was changed to itraconazole and caspofungin. Despite elevated C-reactive protein (CRP) levels and detectable Candida organ lesions, antileukemic therapy was restarted with interleukin 2 at the same time as antimicrobial treatment. Eight weeks after the start of interleukin therapy, CRP levels and organ lesions were decreased significantly irrespective of continuing neutropenia. This case report describes the successful treatment of CDC during neutropenia using combination antifungal therapy and suggests controlled studies to establish optimal therapeutic strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sallah S,Wan JY, Nguyen NP,Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer. 2001;92:1349–1353.
Sallah S, Semelka R, Kelekis N,Worawattanakul S, Sallah W. Diag nosis and monitoring response to treatment of hepatosplenic candidiasis in patients with acute leukemia using magnetic resonance imaging. Acta Haematol. 1998;100:77–81.
Derenski SC, Stevens DA. Caspofungin. Clin Infect Dis. 2003;36: 1445–1457.
Quintini G, Barbera V, Gambino R, Spadola V, Minardi V, Mariani G. Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunirubucin and fluconazole. Haematologica. 2001;86:E18.
Colovic M, Lazarevic V, Colovic R, et al. Hepatosplenic candidiasis after neutropenic phase of acute leukemia. Med Oncol. 1999;16: 139–142.
Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87:535–541.
Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7–14.
Karthaus M, Huebner G, Elser C, Geissler RG, Heil G, Ganser A. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computerassisted serial ultrasound documentation. Ann Hematol. 1998;77: 41–45.
Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am. 2000;14:721–739.
van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246–254.
Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–2029.
Johnsons MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother. 2003;4:807–823.
Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses. 2002;45(suppl 3):56–60.
Diamond RD. Interactions of phagocytic cells with Candida and other opportunistic fungi. Arch Med Res. 1993;24:361–369.
Gaviria JM, vanBurk J-AH, Dale DC, Root RK, Liles WC. Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis. 1999;179:1301–1304.
Rokusz L, Liptay L, Kadar K. Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocytemacrophage colony-stimulating factor combination. Scand J Infect Dis. 2001;33:784–786.
Walsh TJ,Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer. 1995;76:2357–2362.
Katayama K, Koizumi S, Yamagami M, et al. Successful peritransplant therapy in children with active hepatosplenic candidiasis. Int J Hematol. 1994;59:125–130.
Meloni G, Trisolini SM, Capria S, et al. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia. 2002;16:2016–2018.
Maraninchi D,Vey N,Viens P, et al.A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma. 1998;31:343–349.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hübel, K., Chemnitz, J., Brochhagen, H.G. et al. Successful Treatment of Chronic Disseminated Candidiasis with Caspofungin and Itraconazole in a Patient with Progressive Acute Leukemia and Prolonged Neutropenia. Int J Hematol 79, 289–292 (2004). https://doi.org/10.1532/IJH97.E0315
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.E0315